Entero Therapeutics
- Country
- Ownership
- -
- Employees
- 9
- Market Cap
- -
- Introduction
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm involves in therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD,FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
- Conditions
- Cystic FibrosisExocrine Pancreatic Insufficiency
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT05719311
- Locations
- 🇺🇸
Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸The Cystic Fibrosis Institute, Northfield, Illinois, United States
🇺🇸Childrens Lung Specialists, Las Vegas, Nevada, United States
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 166
- Registration Number
- NCT04858425
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States
🇺🇸New Generation Medical Research, Hialeah, Florida, United States
Study of Latiglutenase in T1D/CD Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04839575
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Niclosamide in COVID-19
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Entero Therapeutics
- Registration Number
- NCT04542434
Niclosamide In Moderate COVID-19
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Entero Therapeutics
- Registration Number
- NCT04436458
- Prev
- 1
- 2
- Next
News
Entero Therapeutics to License AI-Powered Clinical Trial Compliance Tech from Data Vault
Entero Therapeutics will license Data Vault's QOLPOM and FotoDigm platforms to enhance clinical trial compliance, particularly for its Phase 3 latiglutenase trial.